Emerging revolutionary treatments for spinal muscular atrophy (SMA) require a fast diagnosis. Also, SMA carrier screening is recommended for all women considering pregnancy. It’s challenging for laboratories to provide timely and comprehensive information for diagnosis and carrier screening. Global diagnostics leader, Asuragen, is working to ensure labs can quickly provide comprehensive information on SMN1 and SMN2.
